Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: Results of the UK ROBUST Trial

British Journal of Haematology

Volumn 170, Issue 1, 2015, Pages 29-39

  Mead, Adam J ^a   Milojkovic, Dragana ^b   Knapper, Steven ^c   Garg, Mamta ^d   Chacko, Joseph ^e   Farquharson, Mira ^f   Yin, John ^g   Ali, Sahra ^h   Clark, Richard E ⁱ   Andrews, Chris ^j   Dawson, Meryem Ktiouet ^j   Harrison, Claire ^k  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d LEICESTER ROYAL INFIRMARY   (United Kingdom)

^e POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^f WESTERN GENERAL HOSPITAL   (United Kingdom)

^g MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^h HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

ⁱ ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^j Novartis Pharmaceuticals Uk Limited   (United Kingdom)

^k GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

Janus kinase inhibitor; Myelofibrosis; Myelofibrosis Symptom Assessment Form; Ruxolitinib; Symptoms

Indexed keywords

ALANINE AMINOTRANSFERASE; RUXOLITINIB; PYRAZOLE DERIVATIVE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BACKACHE; CANCER GROWTH; CANCER SURVIVAL; CAUSE OF DEATH; CONSTIPATION; CONTROLLED STUDY; CONTUSION; COUGHING; DIARRHEA; DISEASE DURATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; FALLING; FATIGUE; FEMALE; FEVER; FLANK PAIN; GOUT; HEADACHE; HUMAN; HYPERHIDROSIS; LETHARGY; LIMB PAIN; LOWER RESPIRATORY TRACT INFECTION; MALE; MOUTH ULCER; MULTICENTER STUDY; MUSCLE SPASM; MYELOFIBROSIS; MYELOFIBROSIS SYMPTOM ASSESSMENT FORM TOTAL SYMPTOM SCORE; NAUSEA; NEUTROPENIA; NIGHT SWEAT; OPEN STUDY; OVERALL SURVIVAL; PARESTHESIA; PATIENT CODING; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; QUALITY OF LIFE; RHINOPHARYNGITIS; RISK ASSESSMENT; SCORING SYSTEM; SELF REPORT; SIDE EFFECT; SKIN DEFECT; SPLEEN LENGTH; SPLEEN SIZE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; UNITED KINGDOM; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN; CLINICAL TRIAL; MIDDLE AGED; PATHOLOGY; PRIMARY MYELOFIBROSIS; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PYRAZOLES; RISK FACTORS;

EID: 84924784206     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13379     Document Type: Article

References (32)

1. Aaronson, N.K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N.J., Filiberti, A., Flechtner, H., Fleishman, S.B. & de Haes, J.C. (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85, 365-376.
2. Abdel-Wahab, O.I. & Levine, R.L. (2009) Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annual Review of Medicine, 60, 233-245.
3. Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N. & Green, A.R.; Cancer Genome Project. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 1054-1061.
4. Brazier, J., Jones, N. & Kind, P. (1993) Testing the validity of the EuroQol and comparing it with the SF-36 health survey questionnaire. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 2, 169-180.
5. Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J.T., Morra, E., Vannucchi, A.M., Mesa, R.A., Demory, J.L., Barosi, G., Rumi, E. & Tefferi, A. (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 113, 2895-2901.
6. Cervantes, F., Vannucchi, A.M., Kiladjian, J.J., Al-Ali, H.K., Sirulnik, A., Stalbovskaya, V., McQuitty, M., Hunter, D.S., Levy, R.S., Passamonti, F., Barbui, T., Barosi, G., Harrison, C.N., Knoops, L. & Gisslinger, H.; COMFORT-II investigators. (2013) Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood, 122, 4047-4053.
7. EuroQol Group. (1990) EuroQol - a new facility for the measurement of health-related quality of life. Health Policy (Amsterdam, Netherlands), 16, 199-208.
8. Harrison, C., Kiladjian, J.J., Al-Ali, H.K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D.S., Levy, R., Knoops, L., Cervantes, F., Vannucchi, A.M., Barbui, T. & Barosi, G. (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. The New England Journal of Medicine, 366, 787-798.
9. James, C., Ugo, V., Le Couedic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. & Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 1144-1148.
10. Klampfl, T., Gisslinger, H., Harutyunyan, A.S., Nivarthi, H., Rumi, E., Milosevic, J.D., Them, N.C., Berg, T., Gisslinger, B., Pietra, D., Chen, D., Vladimer, G.I., Bagienski, K., Milanesi, C., Casetti, I.C., Sant'antonio, E., Ferretti, V., Elena, C., Schischlik, F., Cleary, C., Six, M., Schalling, M., Schonegger, A., Bock, C., Malcovati, L., Pascutto, C., Superti-Furga, G., Cazzola, M. & Kralovics, R. (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. The New England Journal of Medicine, 369, 2379-2390.
11. Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. & Skoda, R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. The New England Journal of Medicine, 352, 1779-1790.
12. Mesa, R.A., Verstovsek, S., Cervantes, F., Barosi, G., Reilly, J.T., Dupriez, B., Levine, R., Le Bousse-Kerdiles, M.C., Wadleigh, M., Campbell, P.J., Silver, R.T., Vannucchi, A.M., Deeg, H.J., Gisslinger, H., Thomas, D., Odenike, O., Solberg, L.A., Gotlib, J., Hexner, E., Nimer, S.D., Kantarjian, H., Orazi, A., Vardiman, J.W., Thiele, J. & Tefferi, A.; International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). (2007a) Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Leukemia Research, 31, 737-740.
13. Mesa, R.A., Niblack, J., Wadleigh, M., Verstovsek, S., Camoriano, J., Barnes, S., Tan, A.D., Atherton, P.J., Sloan, J.A. & Tefferi, A. (2007b) The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer, 109, 68-76.
14. Mesa, R.A., Schwager, S., Radia, D., Cheville, A., Hussein, K., Niblack, J., Pardanani, A.D., Steensma, D.P., Litzow, M.R., Rivera, C.E., Camoriano, J., Verstovsek, S., Sloan, J., Harrison, C., Kantarjian, H. & Tefferi, A. (2009) The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leukemia Research, 33, 1199-1203.
15. Mesa, R.A., Gotlib, J.R., Gupta, V., DiPersio, J.F., Catalano, J., Deininger, M., Shields, A., Miller, C.B., Silber, R.T., Talpaz, M., Winton, E.F., Harvey, J.H., Hare, T., Erickson-Viitanen, S., Koumenis, I., Sun, W., Sandor, V., Levy, R., Kantarjian, H. & Verstovsek, S. (2011) Results using the modified myelofibrosis symptom assessment form (MFSAF v2.0) in COMFORT-I: a randomized, double-blind, phase 3 trial of JAK1/2 inhibitor ruxolitinib vs placebo in myelofibrosis. Haematologica, 96, [abstract 0912], 380 p.
16. Mesa, R.A., Shields, A., Hare, T., Erickson-Viitanen, S., Sun, W., Sarlis, N.J., Sandor, V., Levy, R.S. & Verstovsek, S. (2013a) Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study. Leukemia Research, 37, 911-916.
17. Mesa, R.A., Gotlib, J., Gupta, V., Catalano, J.V., Deininger, M.W., Shields, A.L., Miller, C.B., Silver, R.T., Talpaz, M., Winton, E.F., Harvey, J.H., Hare, T., Erickson-Viitanen, S., Sun, W., Sandor, V., Levy, R.S., Kantarjian, H.M. & Verstovsek, S. (2013b) Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31, 1285-1292.
18. Nangalia, J., Massie, C.E., Baxter, E.J., Nice, F.L., Gundem, G., Wedge, D.C., Avezov, E., Li, J., Kollmann, K., Kent, D.G., Aziz, A., Godfrey, A.L., Hinton, J., Martincorena, I., Van Loo, P., Jones, A.V., Guglielmelli, P., Tarpey, P., Harding, H.P., Fitzpatrick, J.D., Goudie, C.T., Ortmann, C.A., Loughran, S.J., Raine, K., Jones, D.R., Butler, A.P., Teague, J.W., O'Meara, S., McLaren, S., Bianchi, M., Silber, Y., Dimitropoulou, D., Bloxham, D., Mudie, L., Maddison, M., Robinson, B., Keohane, C., Maclean, C., Hill, K., Orchard, K., Tauro, S., Du, M.Q., Greaves, M., Bowen, D., Huntly, B.J., Harrison, C.N., Cross, N.C., Ron, D., Vannucchi, A.M., Papaemmanuil, E., Campbell, P.J. & Green, A.R. (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. The New England Journal of Medicine, 369, 2391-2405.
19. Pikman, Y., Lee, B.H., Mercher, T., McDowell, E., Ebert, B.L., Gozo, M., Cuker, A., Wernig, G., Moore, S., Galinsky, I., DeAngelo, D.J., Clark, J.J., Lee, S.J., Golub, T.R., Wadleigh, M., Gilliland, D.G. & Levine, R.L. (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Medicine, 3, e270.
20. Scott, L.M., Tong, W., Levine, R.L., Scott, M.A., Beer, P.A., Stratton, M.R., Futreal, P.A., Erber, W.N., McMullin, M.F., Harrison, C.N., Warren, A.J., Gilliland, D.G., Lodish, H.F. & Green, A.R. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. The New England Journal of Medicine, 356, 459-468.
21. Swerdlow, S.H., Campo, E., Harrison, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (eds) (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon.
22. Tallantyre, E.C., Paine, S.M., Sharp, C.P., Lowe, J.S. & Gran, B. (2009) Atypical progressive multifocal leukoencephalopathy associated with an unusual JC polyomavirus mutation. Archives of Neurology, 66, 1021-1024.
23. Tavazzi, E., White, M.K. & Khalili, K. (2012) Progressive multifocal leukoencephalopathy: clinical and molecular aspects. Reviews in Medical Virology, 22, 18-32.
24. Tefferi, A., Barosi, G., Mesa, R.A., Cervantes, F., Deeg, H.J., Reilly, J.T., Verstovsek, S., Dupriez, B., Silver, R.T., Odenike, O., Cortes, J., Wadleigh, M., Solberg, Jr, L.A., Camoriano, J.K., Gisslinger, H., Noel, P., Thiele, J., Vardiman, J.W., Hoffman, R., Cross, N.C., Gilliland, D.G. & Kantarjian, H.; IWG for Myelofibrosis Research and Treatment (IWG-MRT). (2006) International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood, 108, 1497-1503.
25. Tefferi, A. (2013) Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 88, 141-150.
26. Tefferi, A., Cervantes, F., Mesa, R., Passamonti, F., Verstovsek, S., Vannucchi, A.M., Gotlib, J., Dupriez, B., Pardanani, A., Harrison, C., Hoffman, R., Gisslinger, H., Kroger, N., Thiele, J., Barbui, T. & Barosi, G. (2013) Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European LeukemiaNet (ELN) consensus report. Blood, 122, 1395-1398.
27. Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellstrom-Lindberg, E., Tefferi, A. & Bloomfield, C.D. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937-951.
28. Verma, S., Cikurel, K., Koralnik, I.J., Morgello, S., Cunningham-Rundles, C., Weinstein, Z.R., Bergmann, C. & Simpson, D.M. (2007) Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. The Journal of Infectious Diseases, 196, 709-711.
29. Verstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., DiPersio, J., Catalano, J.V., Deininger, M., Miller, C., Silver, R.T., Talpaz, M., Winton, E.F., Harvey, J.H., Arcasoy, M.O., Hexner, E., Lyons, R.M., Paquette, R., Raza, A., Vaddi, K., Erickson-Viitanen, S., Koumenis, I., Sun, W., Sandor, V. & Kantarjian, H.M. (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine, 366, 799-807.
30. Verstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., DiPersio, J.F., Catalano, J.V., Deininger, M.W.N., Miller, C.B., Silver, R.T., Talpaz, M., Winton, E.F., Harvey, J.H., Arcasoy, M.O., Hexner, E.O., Lyons, R.M., Raza, A., Vaddi, K., Sun, W., Peng, W., Sandor, V. & Kantarjian, H. (2013) Long-term outcomes of ruxolitinib therapy in patients with myelofibrosis: 3-year update from COMFORT-I. Blood (ASH Annual Meeting Abstracts), 122, 396.
31. Walters, S.J. & Brazier, J.E. (2005) Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 14, 1523-1532.
32. Wathes, R., Moule, S. & Milojkovic, D. (2013) Progressive multifocal leukoencephalopathy associated with ruxolitinib. The New England Journal of Medicine, 369, 197-198.